WO2006131262A1 - Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations - Google Patents

Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations Download PDF

Info

Publication number
WO2006131262A1
WO2006131262A1 PCT/EP2006/005240 EP2006005240W WO2006131262A1 WO 2006131262 A1 WO2006131262 A1 WO 2006131262A1 EP 2006005240 W EP2006005240 W EP 2006005240W WO 2006131262 A1 WO2006131262 A1 WO 2006131262A1
Authority
WO
WIPO (PCT)
Prior art keywords
xyloglucan
mucoadhesive
pharmaceutical preparations
medical devices
vaginal
Prior art date
Application number
PCT/EP2006/005240
Other languages
French (fr)
Inventor
Giuseppe Bottoni
Paola Maffei
Annalisa Sforzini
Mascia Federici
Carla Caramella
Silvia Rossi
Giuseppe Claudio Viscomi
Original Assignee
Alfa Wassermann S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2008514019A priority Critical patent/JP5118633B2/en
Priority to EP06754047A priority patent/EP1898876B1/en
Application filed by Alfa Wassermann S.P.A. filed Critical Alfa Wassermann S.P.A.
Priority to KR1020077028142A priority patent/KR101337578B1/en
Priority to DK06754047T priority patent/DK1898876T3/en
Priority to BRPI0611400A priority patent/BRPI0611400B8/en
Priority to MX2007015074A priority patent/MX2007015074A/en
Priority to CA2604768A priority patent/CA2604768C/en
Priority to DE602006004451T priority patent/DE602006004451D1/en
Priority to CN2006800176445A priority patent/CN101180036B/en
Priority to PL06754047T priority patent/PL1898876T3/en
Priority to US11/921,286 priority patent/US20090081133A1/en
Publication of WO2006131262A1 publication Critical patent/WO2006131262A1/en
Priority to IL186655A priority patent/IL186655A/en
Priority to NO20076083A priority patent/NO338991B1/en
Priority to US13/277,130 priority patent/US20120088726A1/en
Priority to US13/747,889 priority patent/US20130183325A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams

Definitions

  • the present invention relates to mucoadhesive formulations suitable for the application to human mucous membranes, for use as moisturizing and softening agents or as pharmaceutical release systems for local and/or 5 systemic use.
  • mucosa is a covering membrane of the internal surface of body cavities and organic channels directly or indirectly connected to the exterior, i.e. oral cavity, gastrointestinal tube, respiratory tract and vaginal cavity.
  • mucous 0 membranes are essentially constituted of an epithelium covering the cavity of the organ or the channel's lumen and, more deeply, of a connective tissue ⁇ tunica intestinal or mucous derma) with the supporting function; this tissue may be rich in elastic fibre and lymphocytes.
  • Mucous membranes are wetted by the secretion of glands contained in their thickness or directly produced by 5 the glandular epithelium which constitutes them.
  • Such fluids mainly consist of water, glycoproteins (mucin), lipids, mineral salts and enzymes.
  • the basic functions of all secreted fluids are to modulate interactions between epithelial cells and their environment by means of a lubrication/hydratation process, of a control process at chemical-physical and microbiological level of the 0 "ecosystem” cavities acting also as defence barrier against pathogens.
  • a reduced secretion of fluids causes the inevitable onset of "dryness", a symptom connected with of a large number of pathological conditions.
  • mucous dryness is in most cases the first clinical symptom of Sj ⁇ rgren Syndrome, a systemic autoimmune disease affecting exocrine glands causing 5 the progressive loss of their activity.
  • the clinical picture is characterized by reduction of lachrymal and salivar secretions (ocular dryness with keratoconjunctivitis, xerostomia, dysphagia) and reduction of vaginal mucous and bronchial tree secretions.
  • Vaginal mucous membrane is constituted of a non-keratinised stratified pavement epithelium.
  • the intermediate layers of the epithelium show glycogen-rich cells.
  • the epithelium lies on an lamina basement without glands and rich in vessels, most of all veins.
  • the mucous membrane under physiological conditions is covered by a lubricating fluid mainly produced by uterine endometrium, endocervical glands (cervical mucus) and main vestibular glands (Bartolino glands) (J.R. Berman et al., Eur. Urol., 38, 20-29, 2000).
  • Vaginal fluid in fertile women is normally acidic (pH 3.5-4.5), while before puberty as well as after menopause secretions tend to be alkaline.
  • the vaginal fluid is viscous, water represents the major component (90-99%), while mucin (glycoprotein) amounts to 0.5-5% by weight. Mucin is responsible for the chemical-physical characteristics of the vaginal fluid, particularly viscosity and mucoadhesive properties.
  • Vaginal fluid also contains plasmatic proteins, enzymes (protease, betaglucoronidase, acid and alkaline phosphatase and estherase), amino acids, cholesterol, lipids, inorganic ions, lactic acid, acetic acid and desquamated epithelial cells.
  • a serum transudate is also is present in the vagina.
  • vaginal mucus production and the concentrations of the different components vary during menstrual period (M. M. Garrey, "Ginecologia Illustrata”, Ed. Il Pensiero Scientifico, 1974).
  • the production of vaginal mucus is mainly controlled by sexual steroids which affect the biophysical properties of the secretion. Hormonal alterations can be the cause of a reduction in the mucus production with a consequent reduction of the vaginal mucous lubrication (vaginal dryness). This condition may often turn up during menopause when, as a consequence of the reduction of circulating estrogenic levels, genitals undergo anatomical modifications with a consequent change in morphological and functional characteristics.
  • Ovaries become sclerotized, endometrium atrophises, glandular component tends to disappear, cervical channel stenotises and cervical mucus disappears, vagina narrows and loses its elasticity, vaginal walls became thinner, atrophic and dry. The regression is very evident in both vaginal and neck corions and plasmatic transudation disappears.
  • the reduced production of mucus exposes the mucous membrane to a greater vulnerability versus infections as a consequence of the abrasions that can occur during the sexual intercourse.
  • Such susceptibility can be further increased by vaginal alterations (reduction of intracellular glycogen, modifications of pH and microflora) typical of menopause (G. B. Candiani, V. Danesino, A. Gastaldi, La Clinica Ostetrica e Ginecologica, Ed. Masson, 1992).
  • This condition causes a symptomatology characterized by dyspareunia, burning and itch with not negligible psychological and sexual rebounds.
  • Transient, periodical or def ⁇ nitve vaginal dryness is a common problem that can appear at any time of life in women, from puberty to menopause and can often make sexual intercourse painful or even impossible.
  • menopause which evidently represents the most common condition causing vaginal dryness
  • fauces dryness can be the symptom of several clinical pictures related to endocrine pathologies, psychic alterations like anxiety and depression, nutritional deficiencies, cranial nerves lesions; or also the adverse side-effect of several drugs such as anti-depressants, ACE-inhibitors, chemotherapeutics/radiotherapeutics, sympathomi-metic, anti-retroviral, anxiolytic and sedative, anti- arrhythmic, anti-inflammatory, antihypertensive, anti-histaminic, anti-ulcer and neuroleptic agents.
  • drugs such as anti-depressants, ACE-inhibitors, chemotherapeutics/radiotherapeutics, sympathomi-metic, anti-retroviral, anxiolytic and sedative, anti- arrhythmic, anti-inflammatory, antihypertensive, anti-histaminic, anti-ulcer and neuroleptic agents.
  • a reduction of the secretion also involves manifestations related to an alteration of the protective and regulative system of physiological equilibrium.
  • a reduced salivary production can be responsible for oral dryness (xerostomia), taste alteration, increasing of caries onset and gingival inflammation, stomatitis and mastication problems.
  • Fauces dryness can also be a symptom related to clinical conditions such as subacute or chronic pharyngitis and chronic laryngitis; the etiological agents of these diseases are pathogenic microbial agents and also irritating agents like atmospheric pollutants, tobacco smoke, cold and dry air, chronic irritation caused by gastric acid material (gastroesophageal reflux), (J.Woodley, Bioadhesion, New possibilities for Drug Administrations, Clin. Pharmacokinetic, 40, 77-84, 2001).
  • the organs, in which the mucous membranes are present are also subjected to specific pathologies and moreover they are able to absorb drugs, it is useful to make available medicaments releasing drugs in such sites.
  • bioadhesive polymers or substances able to intimately adhere to the biological membranes, can be used, for example as disclosed in EP 0770384B l for preparations for the vaginal use.
  • Xyloglucans are a class of polysaccharides structurally similar to cellulose and intimately associated to it in the cell wall in superior plants.
  • xyloglucans are one of the main components, most likely acting as an energetic reserve, of plants seeds such as Tamarindus Indica original from India and South-East Asia, Detarium senegalense Gmelin diffused in Africa
  • Xyloglucans are characterized by a main chain of (l ,4)- ⁇ -D-Glucan substituted with side chains of ⁇ -D-xylopyranose and ⁇ -D- galactopyranosyl -(l,2)- ⁇ -D-xylopyranose linked to glycan residues through a ⁇ (l ,6) bond.
  • the distribution of the residues in the side chains is different in xyloglucans of different types.
  • Three oligomeric units have been identified in the xyloglucans structure, namely monosaccharides, octasaccharides and heptasaccharides which differ from each other in the number of galactose side chains (U. Hiroshi, Trends in Glycoscience and Glycotechnology, 14, 355-376, 2002).
  • xyloglucans The main use of xyloglucans is in human and animal nutrition. Furthemore, flour obtained by seeds of the above mentioned plants, containing xyloglucans, is commonly used in nutritional industry as a stabilizing, gelling and thickening agent.
  • xyloglucans are used as viscosizing agents in products used as lachrymal substitutes, showing a safe toxicological profile even when administered to ophthalmic mucous membrane, which are particularly sensitive to lesions and irritations (M. F. Saettone et al. in US 6,056,950).
  • WO 9729777 discloses a xyloglucan preparation, partially degraded with an enzyme such as galactosidase, for use as an ingredient in the preparation of controlled-release formulations ).
  • the glycerol content is directly related to the controlled release behaviour of this xyloglucan preparation, and mucoadhesiveness persists even reducing the viscosity of the solution.
  • Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to
  • glycerol 70% by weight of glycerol.
  • These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system.
  • the combinations of the invention can be added with active principles and excipients known by those skilled in the art, for the preparation of pharmaceutical preparations or medical devices for human use that are a further object of the invention.
  • These pharmaceutical preparations and medical devices can be formulated as solutions, gels, ovules, sprays, mouthwashes, creams, ointments, vaginal washes and any other suitable administration systems.
  • a great number of active principles can be used in the present invention, preferably antibiotics, antimycotics, antiprotozoals, antivirals, antiinflammatories, disinfectants, chemotherapeutics, analgesics, mucolytics, antitussives, decongestants, calcium absorption regulators, hormones and vaccines.
  • the xyloglucan purified of the present invention is obtained by purification of vegetable extracts of xyloglucans, or commercially available unfinished products with different purity grade for the use in nutritional industry.
  • the purification is carried out according to the following process.
  • a 0.5% to 5% suspension, preferably 1% to 2%, of raw powder xyloglucan extract is prepared in cold distilled water.
  • the suspension is then poured in four times the volume of boiling distilled water and the solution is kept under boiling for 15 to 30 minutes under stirring.
  • the resulting solution is left to standleft to stand for 10 to 20 hours until the contaminant proteins and fibres precipitate.
  • the solution is then centrifuged at 4000 - 8000 rpm for a time between 15 and 30 minutes.
  • the supernatant is filtered through a 6 ⁇ m polypropylene filter and the filtrate is further centrifuged at 12000 - 18000 rpm for a time between 30 and 60 minutes.
  • the supernatant can then be sterilized either by filtration through a 0.22 ⁇ m polypropylene filter or in autoclave at 121 0 C for a time between 20 and 40 minutes.
  • the resulting solution can be directly used as such or lyophilized.
  • the described process affords the purified xyloglucan in a yield between 30% and 80% in respect of the starting product.
  • Such purification process affords xyloglucans suitable for the pharmaceutical use, in particular providing a safety profile for use in humans, more particularly for the application to mucous membranes.
  • the purification process of the invention provides a product with constant technological properties which guarantee reproducibility in terms of viscosity and mucoadhesiveness. Viscosity is one of more important parameters which characterize a product intended for mucoadhesive preparations.
  • the process of the invention provides a purified xyloglucan with viscosity suitable for the scopes of invention., as determined on a 2% by weight aqueous solution by using a rotational viscosimeter at the temperature of 25 0 C operating at a shear rate of 200 sec "1 and a rest time of 15 minutes. The resulting viscosity values can change depending on the starting raw product.
  • the viscosity values suitable for the use within the scopes of the present invention range between 150 and 800 mPa-sec.
  • the purification process provides a remarkable reduction of protein impurities present in the starting material.
  • Xyloglucans free from protein impurities are necessary as mucous sites are particularly sensitive to irritations.
  • administration to the oral cavity can trigger anaphylactic reactions.
  • an upper limit of UV absorbance at 280 nm which is an indirect measure of residual proteins, has been introduced.
  • the purified xyloglucans suitable for the invention should have an absorption value at 280 nm lower than 0.5 abs units when measured in a 2% by weight aqueous solution at the temperature of
  • Figure 1 reports the mucoadhesiveness profile of formulations containing the purified xyloglucan at increasing glycerol concentrations, according to the data from table 2 of example 3,. Such profile shows the synergetic effect of glycerol and xyloglucan in increasing mucoadhesiveness.
  • Figure 2 shows that the increase in mucoadhesiveness is not related to viscosity values of the respective solutions, according to the data from table 2 of example 3.
  • table 2 of example 3 shows that significant levels of mucoadhesiveness are assured also at low viscosity values, for instance at values lower than 30 mPa-sec.
  • topical preparations might be subject to two phenomena both having a potentially negative impact on mucoadhesiveness: in fact near the mucous surface, the combined action of temperature and physiological fluids will induce a reduction of viscosity and a dilution effect on the preparation.
  • the xyloglucan-glycerol preparation of the invention maintains mucoadhesiveness at low concentrations and at a level unrelated to viscosity.
  • the addition of glycerol in concentrations between 10% and 70% by weight to solutions of purified xyloglucan at a concentration between 0.05% and 5% by weight provides a controlled release of drugs in a manner directly related to the glycerol content and unrelated to the viscosity of the final solution.
  • the controlled release property combined with the mucoadhesive property provides the constant, prolonged release of the active ingredient at the site of action, as reported in Table 3 for diclofenac.
  • the formulation containing xyloglucan and glycerol of the invention has been evaluated for safety: the obtained results, reported in Examples 11 , 12, 13, prove good local tolerability, absence of sensitisation and citotoxicity properties.
  • the particular mucoadhesiveness together with the controlled release properties of the products of the invention is a determinant characteristic also for the preparation of innovative pharmaceutical forms for drugs release.
  • the advantages are connected to the possibility to keep the pharmaceutical ingredient active at the action site for longer times, increasing the drug bioavailability.
  • the prolonged time of permanence, combined with the drug controlled release allows to decrease the administration frequency.
  • Such properties can be useful for the administration of drugs to oral, nasal and vaginal mucous membranes.
  • the present invention also relates to medical devices and pharmaceutical preparations containing, in addition to pharmaceutical active ingredients and excipients, 0.05% to 5% by weight of purified natural polymer having xyloglucan structure and 10% to 70% by weight of glycerol.
  • preferred active principles are selected from antiinflammatory agents, such as diclofenac and benzidamine, hormones such as progesterone and calcitonin.
  • Preferred formulation forms are ovules, gels, lavages and sprays.
  • Examples of pharmaceutical preparations according to the invention are an oropharyngeal spray containing sodium diclofenac, a vaginal gel containing progesterone, a vaginal lavage containing benzidamine hydrochloride and a nasal spray containing calcitonin.
  • Examples of medical devices according to the invention are a vaginal ovule having hydrating properties and an oropharyngeal spray having softening properties.
  • a suspension is prepared by adding 200 ml cold distilled water to 20 g Glyloid ® 3S (Dainippon) under powder form.
  • the suspension is poured into 800 ml of boiling distilled water and the solution is kept under boiling for 20 minutes under magnetic stirring.
  • the resulting solution is left to stand for 12 hours, then centrifuged at 5000 rpm for 20 minutes.
  • the supernatant is filtered through a 6 ⁇ m polypropylene filter and the resulting solution is further centrifuged at 15000 rpm for 30 minutes. Then the solution is sterilized through a 0.22 ⁇ m polypropylene filter.
  • Finally the resulting solution is lyophilized obtaining 14 g of purified xyloglucan preparation.
  • the viscosity of the purified product at the concentration of 2% by weight in an aqueous solution is 229 mPa-sec, measured at the temperature of 25 C with a "shear rate" of 200 sec ' 1 and at a rest time of 15 minutes.
  • the absorbance of a 2% by weight aqueous solution at the temperature of 25°C, measured at 280 nm, is 0.2 abs units.
  • Sodium methyl-paraoxybenzoate is dissolved in water at the temperature of 70 0 C, then disodium monobasic phosphonate, sodium diclofenac and glycerol are added to the cooled solution. The solution is kept under stirring until complete dissolution. Purified xyloglucan is then added and the solution is kept under stirring for 8 hours until complete swelling, then is brought to 100 ml with water.
  • the viscosity of sodium diclofenac solutions prepared according to Example 2 was measured using a rheostat having a measure geometry with a cone plate C 60/1, a "shear rate" of 200 sec " 1 and a rest time of 3 minutes.
  • the test is carried out by gliding the sample on an inclined inert support covered with a gastric porcine mucin layer.
  • the absorption on the mucin layer is valued referring to the absorption of the same sample on the non-covered inclined inert support.
  • Aloe barbadensis cryodehydrated extract, fish gelatine, sodium methyl p-hydroxybenzoate, sodium ethyl p-hydroxybenzoate and sodium propyl p-hydroxybenzoate are solubilized at 70 0 C in 15 ml of water. After complete solubilization, the solution is cooled to 25°C and the purified xyloglucan is added. The solution is kept under stirring for about 8 hours and after complete swelling is brought to the temperature of 45 0 C and glycerol is added.
  • deionized water is added to 30 grams total weight and the product is distributed into 10 moulds.
  • Methyl parahydroxybenzoate is added at 70 0 C in water. After complete solubilization and cooling of the solution, hydrogenated palm oil glycerides of containing the previously solubilized progesterone are added. After complete mixing, purified xyloglucan is added and the mixture it is kept under stirring for 8 hours until complete swelling of the polymer. Lastly glycerol is added and the final solution is stirred.
  • Trimethylcetylammonium p-toluenesulphonate, rose fragrance and benzidamine hydrochloride are solubilized in water. Purified xyloglucan is added after complete solubilization and the solution is kept under stirring for 8 hours until complete swelling of the polymer. Glycerol is added and the final solution is mixed until complete homogenisation.
  • Sodium chloride, citric acid monohydrate, sodium citrate dihydrate and hydrochloric acid are added to 65 ml of water. The mixture is kept under stirring until complete dissolution and then 10 ml of water containing the previously solubilized calcitonin are added. The purified xyloglucan is added, keeping stirring for 8 hours until complete swelling of the polymer. Then glycerol is added, the solution is mixed and water is added to the necessary weight.
  • the natural extracts, potassium sorbate and monobasic sodium phosphate monohydrate are added to 65 ml of water.
  • the purified xyloglucan is added, keeping stirring for 8 hours until complete dissolution. Then water is added to the necessary volume.
  • the goal of the open study was to evaluate the treatment's efficaciousness with the ovules of Example 4 in reducing the symptom train, like dyspareunia, vulvar burning and itch, connected to the vaginal dryness.
  • the clinical end point has been evaluated by using a score scale between 0 (absent symptomatology) and 5 (very intense symptomatology).
  • the local effects of the oropharyngeal spray of Example 9, on oral cavity mucous membranes were determined by examining local tissue changes after repeated placement of the test item into the cheek pouch of the Syrian hamster, over a period of 7 days.
  • Control group animals were treated with sterile water for the same period of time. No indications of a systemic effect of the test were observed during the treatment period. A slight mucous irritation was observed in animals treated with the medical preparation approximately 1 hour after the last application and no reactions were observed 24 hours later, thus proving the good tolerability in the hamster oral cavity mucous membranes.
  • Example 13 Cell toxicity assay of a solution containing xyloglucan and glycerol
  • test item was solubilized in culture medium and concentrations used were 39.1 ; 78.1 ; 156; 313; 625; 1250; 2500 and 5000 micrograms/millilitre. Cytotoxicity was analysed after 24 hours treatment time. No change in the morphology of the cells and no relevant reduction in neutral red uptake was observed after treatment with the test item in any experiments at any concentration tested.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Otolaryngology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)

Abstract

Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients.

Description

MUCOADHESIVE XYLOGLUCAN-CONTAINING FORMULATIONS USEFUL IN MEDICAL DEVICES AND IN PHARMACEUTICAL FORMULATIONS
Field of the invention
The present invention relates to mucoadhesive formulations suitable for the application to human mucous membranes, for use as moisturizing and softening agents or as pharmaceutical release systems for local and/or 5 systemic use.
The mucosa is a covering membrane of the internal surface of body cavities and organic channels directly or indirectly connected to the exterior, i.e. oral cavity, gastrointestinal tube, respiratory tract and vaginal cavity. Despite some differences typical of every single apparatus, mucous 0 membranes are essentially constituted of an epithelium covering the cavity of the organ or the channel's lumen and, more deeply, of a connective tissue {tunica propria or mucous derma) with the supporting function; this tissue may be rich in elastic fibre and lymphocytes. Mucous membranes are wetted by the secretion of glands contained in their thickness or directly produced by 5 the glandular epithelium which constitutes them. Such fluids mainly consist of water, glycoproteins (mucin), lipids, mineral salts and enzymes. The basic functions of all secreted fluids are to modulate interactions between epithelial cells and their environment by means of a lubrication/hydratation process, of a control process at chemical-physical and microbiological level of the 0 "ecosystem" cavities acting also as defence barrier against pathogens.
A reduced secretion of fluids causes the inevitable onset of "dryness", a symptom connected with of a large number of pathological conditions. In fact, mucous dryness is in most cases the first clinical symptom of Sjόrgren Syndrome, a systemic autoimmune disease affecting exocrine glands causing 5 the progressive loss of their activity. The clinical picture is characterized by reduction of lachrymal and salivar secretions (ocular dryness with keratoconjunctivitis, xerostomia, dysphagia) and reduction of vaginal mucous and bronchial tree secretions.
Vaginal mucous membrane is constituted of a non-keratinised stratified pavement epithelium. The intermediate layers of the epithelium show glycogen-rich cells. The epithelium lies on an lamina propria without glands and rich in vessels, most of all veins. The mucous membrane under physiological conditions is covered by a lubricating fluid mainly produced by uterine endometrium, endocervical glands (cervical mucus) and main vestibular glands (Bartolino glands) (J.R. Berman et al., Eur. Urol., 38, 20-29, 2000).
Vaginal fluid in fertile women is normally acidic (pH 3.5-4.5), while before puberty as well as after menopause secretions tend to be alkaline. The vaginal fluid is viscous, water represents the major component (90-99%), while mucin (glycoprotein) amounts to 0.5-5% by weight. Mucin is responsible for the chemical-physical characteristics of the vaginal fluid, particularly viscosity and mucoadhesive properties. Vaginal fluid also contains plasmatic proteins, enzymes (protease, betaglucoronidase, acid and alkaline phosphatase and estherase), amino acids, cholesterol, lipids, inorganic ions, lactic acid, acetic acid and desquamated epithelial cells. In addition to vaginal mucus, a serum transudate is also is present in the vagina.
Mucus production and the concentrations of the different components vary during menstrual period (M. M. Garrey, "Ginecologia Illustrata", Ed. Il Pensiero Scientifico, 1974). The production of vaginal mucus is mainly controlled by sexual steroids which affect the biophysical properties of the secretion. Hormonal alterations can be the cause of a reduction in the mucus production with a consequent reduction of the vaginal mucous lubrication (vaginal dryness). This condition may often turn up during menopause when, as a consequence of the reduction of circulating estrogenic levels, genitals undergo anatomical modifications with a consequent change in morphological and functional characteristics. Ovaries become sclerotized, endometrium atrophises, glandular component tends to disappear, cervical channel stenotises and cervical mucus disappears, vagina narrows and loses its elasticity, vaginal walls became thinner, atrophic and dry. The regression is very evident in both vaginal and neck corions and plasmatic transudation disappears.
The reduced production of mucus exposes the mucous membrane to a greater vulnerability versus infections as a consequence of the abrasions that can occur during the sexual intercourse. Such susceptibility can be further increased by vaginal alterations (reduction of intracellular glycogen, modifications of pH and microflora) typical of menopause (G. B. Candiani, V. Danesino, A. Gastaldi, La Clinica Ostetrica e Ginecologica, Ed. Masson, 1992). This condition causes a symptomatology characterized by dyspareunia, burning and itch with not negligible psychological and sexual rebounds.
Transient, periodical or defϊnitve vaginal dryness is a common problem that can appear at any time of life in women, from puberty to menopause and can often make sexual intercourse painful or even impossible. In addition to menopause, which evidently represents the most common condition causing vaginal dryness, many other causes exist of either endocrine (reduced levels of circulating extrogens) or non-endocrinel nature, such as hysterectomy/ovariectomy, use of oral contraceptives, amenorrhoea, vaginal mucous membrane irritation caused by microbial or chemical agents, treatments with particular drugs, Sjorgren Syndrome, diabetes mellitus and psychic alterations.
As far as oral cavity mucous membrane is concerned, fauces dryness can be the symptom of several clinical pictures related to endocrine pathologies, psychic alterations like anxiety and depression, nutritional deficiencies, cranial nerves lesions; or also the adverse side-effect of several drugs such as anti-depressants, ACE-inhibitors, chemotherapeutics/radiotherapeutics, sympathomi-metic, anti-retroviral, anxiolytic and sedative, anti- arrhythmic, anti-inflammatory, antihypertensive, anti-histaminic, anti-ulcer and neuroleptic agents.
A reduction of the secretion also involves manifestations related to an alteration of the protective and regulative system of physiological equilibrium.
For example a reduced salivary production can be responsible for oral dryness (xerostomia), taste alteration, increasing of caries onset and gingival inflammation, stomatitis and mastication problems.
Fauces dryness can also be a symptom related to clinical conditions such as subacute or chronic pharyngitis and chronic laryngitis; the etiological agents of these diseases are pathogenic microbial agents and also irritating agents like atmospheric pollutants, tobacco smoke, cold and dry air, chronic irritation caused by gastric acid material (gastroesophageal reflux), (J.Woodley, Bioadhesion, New possibilities for Drug Administrations, Clin. Pharmacokinetic, 40, 77-84, 2001).
In the light of the above considerations, it is useful to provide medical devices and pharmaceutical preparations able to reduce or to remove the negative effects directly and/or indirectly related to mucous dryness.
Moreover, since the organs, in which the mucous membranes are present, are also subjected to specific pathologies and moreover they are able to absorb drugs, it is useful to make available medicaments releasing drugs in such sites.
For such purposes bioadhesive polymers, or substances able to intimately adhere to the biological membranes, can be used, for example as disclosed in EP 0770384B l for preparations for the vaginal use. Xyloglucans are a class of polysaccharides structurally similar to cellulose and intimately associated to it in the cell wall in superior plants.
Moreover xyloglucans are one of the main components, most likely acting as an energetic reserve, of plants seeds such as Tamarindus Indica original from India and South-East Asia, Detarium senegalense Gmelin diffused in Africa
(in particular in Nigeria), Afzelia africana diffused in Central and East Africa and also in savannas and forests near East Africa coast and Jatoba.
Xyloglucans are characterized by a main chain of (l ,4)-β-D-Glucan substituted with side chains of α-D-xylopyranose and β-D- galactopyranosyl -(l,2)-α-D-xylopyranose linked to glycan residues through a α(l ,6) bond. The distribution of the residues in the side chains is different in xyloglucans of different types. Three oligomeric units have been identified in the xyloglucans structure, namely monosaccharides, octasaccharides and heptasaccharides which differ from each other in the number of galactose side chains (U. Hiroshi, Trends in Glycoscience and Glycotechnology, 14, 355-376, 2002).
The main use of xyloglucans is in human and animal nutrition. Furthemore, flour obtained by seeds of the above mentioned plants, containing xyloglucans, is commonly used in nutritional industry as a stabilizing, gelling and thickening agent.
The use of xyloglucans in medical devices or as a component in pharmaceutical preparations is also reported, although less frequently. For example, xyloglucans are used as viscosizing agents in products used as lachrymal substitutes, showing a safe toxicological profile even when administered to ophthalmic mucous membrane, which are particularly sensitive to lesions and irritations (M. F. Saettone et al. in US 6,056,950). WO 9729777 (M. Shozo et al.,) discloses a xyloglucan preparation, partially degraded with an enzyme such as galactosidase, for use as an ingredient in the preparation of controlled-release formulations ). According to this patent, partial removal of galactose residues from xyloglucan provides high gelling properties, so that an active principle incorporated in such gel can be gradually released in the application site. It has now been found, and this is the object of the present invention, that preparations of suitably purified xyloglucans combined with appropriate quantities of glycerol show unexpected mucoadhesive properties. The presence of glycerol unexpectedly increases xyloglucan mucoadhesiveness.
Moreover, the glycerol content is directly related to the controlled release behaviour of this xyloglucan preparation, and mucoadhesiveness persists even reducing the viscosity of the solution.
Description of the invention
Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to
70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. The combinations of the invention can be added with active principles and excipients known by those skilled in the art, for the preparation of pharmaceutical preparations or medical devices for human use that are a further object of the invention.
These pharmaceutical preparations and medical devices can be formulated as solutions, gels, ovules, sprays, mouthwashes, creams, ointments, vaginal washes and any other suitable administration systems.
A great number of active principles can be used in the present invention, preferably antibiotics, antimycotics, antiprotozoals, antivirals, antiinflammatories, disinfectants, chemotherapeutics, analgesics, mucolytics, antitussives, decongestants, calcium absorption regulators, hormones and vaccines.
The xyloglucan purified of the present invention is obtained by purification of vegetable extracts of xyloglucans, or commercially available unfinished products with different purity grade for the use in nutritional industry.
The purification is carried out according to the following process. A 0.5% to 5% suspension, preferably 1% to 2%, of raw powder xyloglucan extract is prepared in cold distilled water. The suspension is then poured in four times the volume of boiling distilled water and the solution is kept under boiling for 15 to 30 minutes under stirring. The resulting solution is left to standleft to stand for 10 to 20 hours until the contaminant proteins and fibres precipitate. The solution is then centrifuged at 4000 - 8000 rpm for a time between 15 and 30 minutes. The supernatant is filtered through a 6 μm polypropylene filter and the filtrate is further centrifuged at 12000 - 18000 rpm for a time between 30 and 60 minutes. The supernatant can then be sterilized either by filtration through a 0.22 μm polypropylene filter or in autoclave at 1210C for a time between 20 and 40 minutes. The resulting solution can be directly used as such or lyophilized. The described process affords the purified xyloglucan in a yield between 30% and 80% in respect of the starting product.
Such purification process affords xyloglucans suitable for the pharmaceutical use, in particular providing a safety profile for use in humans, more particularly for the application to mucous membranes. The purification process of the invention provides a product with constant technological properties which guarantee reproducibility in terms of viscosity and mucoadhesiveness. Viscosity is one of more important parameters which characterize a product intended for mucoadhesive preparations. The process of the invention provides a purified xyloglucan with viscosity suitable for the scopes of invention., as determined on a 2% by weight aqueous solution by using a rotational viscosimeter at the temperature of 250C operating at a shear rate of 200 sec"1 and a rest time of 15 minutes. The resulting viscosity values can change depending on the starting raw product. The viscosity values suitable for the use within the scopes of the present invention range between 150 and 800 mPa-sec.
Moreover, the purification process provides a remarkable reduction of protein impurities present in the starting material. Xyloglucans free from protein impurities are necessary as mucous sites are particularly sensitive to irritations. On the other hand, administration to the oral cavity can trigger anaphylactic reactions. For this reason, according to the invention an upper limit of UV absorbance at 280 nm, which is an indirect measure of residual proteins, has been introduced. The purified xyloglucans suitable for the invention should have an absorption value at 280 nm lower than 0.5 abs units when measured in a 2% by weight aqueous solution at the temperature of
25°C.
Figure 1 reports the mucoadhesiveness profile of formulations containing the purified xyloglucan at increasing glycerol concentrations, according to the data from table 2 of example 3,. Such profile shows the synergetic effect of glycerol and xyloglucan in increasing mucoadhesiveness. Figure 2 shows that the increase in mucoadhesiveness is not related to viscosity values of the respective solutions, according to the data from table 2 of example 3. Finally, table 2 of example 3 shows that significant levels of mucoadhesiveness are assured also at low viscosity values, for instance at values lower than 30 mPa-sec.
The latter considerations are particularly relevant in view of the applications considered for the present invention. As a matter of fact, after administration onto mucosa, topical preparations might be subject to two phenomena both having a potentially negative impact on mucoadhesiveness: in fact near the mucous surface, the combined action of temperature and physiological fluids will induce a reduction of viscosity and a dilution effect on the preparation. Conversely, the xyloglucan-glycerol preparation of the invention, maintains mucoadhesiveness at low concentrations and at a level unrelated to viscosity.
According to the invention, the addition of glycerol in concentrations between 10% and 70% by weight to solutions of purified xyloglucan at a concentration between 0.05% and 5% by weight provides a controlled release of drugs in a manner directly related to the glycerol content and unrelated to the viscosity of the final solution.
The controlled release of drug from solutions, prepared as described in Example 2 and reported in Table 1 , has been demonstrated by measuring the drug release trough Franz cell over time.
The controlled release property combined with the mucoadhesive property provides the constant, prolonged release of the active ingredient at the site of action, as reported in Table 3 for diclofenac. The formulation containing xyloglucan and glycerol of the invention, has been evaluated for safety: the obtained results, reported in Examples 11 , 12, 13, prove good local tolerability, absence of sensitisation and citotoxicity properties.
The efficacy and safety of the combination of the present invention is also shown by the clinical study reported in Example 10, wherein the use of a medical device in form of vaginal ovule afforded very good results in the treatment of dyspareunia due to vaginal dryness.
The particular mucoadhesiveness together with the controlled release properties of the products of the invention is a determinant characteristic also for the preparation of innovative pharmaceutical forms for drugs release. The advantages are connected to the possibility to keep the pharmaceutical ingredient active at the action site for longer times, increasing the drug bioavailability. Furthermore, the prolonged time of permanence, combined with the drug controlled release, allows to decrease the administration frequency. Such properties can be useful for the administration of drugs to oral, nasal and vaginal mucous membranes.
The present invention also relates to medical devices and pharmaceutical preparations containing, in addition to pharmaceutical active ingredients and excipients, 0.05% to 5% by weight of purified natural polymer having xyloglucan structure and 10% to 70% by weight of glycerol.
According to the present invention, preferred active principles are selected from antiinflammatory agents, such as diclofenac and benzidamine, hormones such as progesterone and calcitonin. Preferred formulation forms are ovules, gels, lavages and sprays.
Examples of pharmaceutical preparations according to the invention are an oropharyngeal spray containing sodium diclofenac, a vaginal gel containing progesterone, a vaginal lavage containing benzidamine hydrochloride and a nasal spray containing calcitonin.
Examples of medical devices according to the invention are a vaginal ovule having hydrating properties and an oropharyngeal spray having softening properties.
Said medical devices and pharmaceutical preparations are described in more detail in the following examples.
Example 1
Preparation of a purified xyloglucan
A suspension is prepared by adding 200 ml cold distilled water to 20 g Glyloid® 3S (Dainippon) under powder form. The suspension is poured into 800 ml of boiling distilled water and the solution is kept under boiling for 20 minutes under magnetic stirring. The resulting solution is left to stand for 12 hours, then centrifuged at 5000 rpm for 20 minutes. The supernatant is filtered through a 6 μm polypropylene filter and the resulting solution is further centrifuged at 15000 rpm for 30 minutes. Then the solution is sterilized through a 0.22 μm polypropylene filter. Finally the resulting solution is lyophilized obtaining 14 g of purified xyloglucan preparation.
The viscosity of the purified product at the concentration of 2% by weight in an aqueous solution is 229 mPa-sec, measured at the temperature of 25 C with a "shear rate" of 200 sec' 1 and at a rest time of 15 minutes.
The absorbance of a 2% by weight aqueous solution at the temperature of 25°C, measured at 280 nm, is 0.2 abs units.
Example 2 Preparation of solutions containing sodium diclofenac
Sodium methyl-paraoxybenzoate is dissolved in water at the temperature of 700C, then disodium monobasic phosphonate, sodium diclofenac and glycerol are added to the cooled solution. The solution is kept under stirring until complete dissolution. Purified xyloglucan is then added and the solution is kept under stirring for 8 hours until complete swelling, then is brought to 100 ml with water.
The compositions of sodium diclofenac solutions are reported in Table 1. Table 1
Figure imgf000013_0001
diclofenac
The viscosity of sodium diclofenac solutions prepared according to Example 2 was measured using a rheostat having a measure geometry with a cone plate C 60/1, a "shear rate" of 200 sec" 1 and a rest time of 3 minutes.
The in vitro measurement of the mucoadhesiveness of the solutions prepared according to Example 2 was carried out with the method of inclined plane as described by Sandri G. et al. (J. Pharm. Pharmacol., 5_6, 1083-1090,
2004). The test is carried out by gliding the sample on an inclined inert support covered with a gastric porcine mucin layer. The absorption on the mucin layer is valued referring to the absorption of the same sample on the non-covered inclined inert support.
500 mg of each sample of the solutions reported in Table 1 containing the purified xyloglucan are placed on the higher point of the plane inclined at 60° and the mixture portion gliding on the plane in a time of 2 minutes is collected and measured by weighing. The viscosity and mucoadhesiveness values of the sodium diclofenac solutions described in Example 2 are reported in Table 2. Table 2
Figure imgf000014_0001
solution
The controlled release properties of a solution containing sodium diclofenac prepared according to Example 2, have been evaluated measuring the washability of the viscous solutions on Franz cell.
The solutions, in the equipment thermostated at 37°C, were washed with phosphate buffer at pH 7.4 and the quantity of active ingredient released was measured after 1 , 2, 3 and 4 hours. The percentage on the total quantity of released sodium diclofenac is reported in Table 3.
Table 3
Figure imgf000014_0002
hydrating properties
Aloe barbadensis cryodehydrated extract, fish gelatine, sodium methyl p-hydroxybenzoate, sodium ethyl p-hydroxybenzoate and sodium propyl p-hydroxybenzoate are solubilized at 700C in 15 ml of water. After complete solubilization, the solution is cooled to 25°C and the purified xyloglucan is added. The solution is kept under stirring for about 8 hours and after complete swelling is brought to the temperature of 450C and glycerol is added.
After homogenisation by mixing, deionized water is added to 30 grams total weight and the product is distributed into 10 moulds.
The amounts of each component for the preparation of 10 ovules are reported in Table 4.
Table 4
Figure imgf000015_0001
Example 6
Preparation of a vaginal gel containing progesterone
Methyl parahydroxybenzoate is added at 700C in water. After complete solubilization and cooling of the solution, hydrogenated palm oil glycerides of containing the previously solubilized progesterone are added. After complete mixing, purified xyloglucan is added and the mixture it is kept under stirring for 8 hours until complete swelling of the polymer. Lastly glycerol is added and the final solution is stirred.
The amounts of the various components for the preparation of the vaginal gel are reported in Table 5. Table 5
Figure imgf000016_0001
Example 7
Preparation of a vaginal lavage containing benzidamine hydrochloride
Trimethylcetylammonium p-toluenesulphonate, rose fragrance and benzidamine hydrochloride are solubilized in water. Purified xyloglucan is added after complete solubilization and the solution is kept under stirring for 8 hours until complete swelling of the polymer. Glycerol is added and the final solution is mixed until complete homogenisation.
The amounts of the various components are reported in Table 6.
Table 6
Figure imgf000016_0002
Example 8
Preparation of a nasal spray containing calcitonin
Sodium chloride, citric acid monohydrate, sodium citrate dihydrate and hydrochloric acid are added to 65 ml of water. The mixture is kept under stirring until complete dissolution and then 10 ml of water containing the previously solubilized calcitonin are added. The purified xyloglucan is added, keeping stirring for 8 hours until complete swelling of the polymer. Then glycerol is added, the solution is mixed and water is added to the necessary weight.
The amounts of the various components are reported in Table 7.
Table 7
Figure imgf000017_0001
Example 9
Preparation of an oropharyngeal spray containing natural extracts
The natural extracts, potassium sorbate and monobasic sodium phosphate monohydrate are added to 65 ml of water. The purified xyloglucan is added, keeping stirring for 8 hours until complete dissolution. Then water is added to the necessary volume.
The amounts of the various components are reported in table 8. Table 8
Figure imgf000018_0001
Example 10
Evaluation of the efficaciousness and tolerability of ovules containing purified xyloglucan on volunteers
The effectiveness and safety of ovules prepared according to Example 4 have been evaluated in the treatment of the dyspareunia caused by vaginal dryness in menopausal women not receving substitutive hormonal therapy.
The goal of the open study was to evaluate the treatment's efficaciousness with the ovules of Example 4 in reducing the symptom train, like dyspareunia, vulvar burning and itch, connected to the vaginal dryness.
8 Women aging between 45 and 65 years in menopause for almost 3 years and without active vaginal infections have been enrolled in the study. The treatment scheme has foreseen the administration of the ovule by vaginal route twice a day for a period of 8 days.
The clinical end point has been evaluated by using a score scale between 0 (absent symptomatology) and 5 (very intense symptomatology).
All patients have completed the treatment. The drug resulted well tolerated and efficacious both at local and systemic level, as shown in Table 9. No side reactions have been observed. Table 9
Figure imgf000019_0001
Example 11
Local tolerance study of a preparation containing xyloglucan and glycerol
The local effects of the oropharyngeal spray of Example 9, on oral cavity mucous membranes were determined by examining local tissue changes after repeated placement of the test item into the cheek pouch of the Syrian hamster, over a period of 7 days. One group constituted of 5 male and 5 female animals, was treated daily with the medical preparation at a dose of 0.5 ml for each animal for a total of 3 times in the same day with 2 hours interval, to give a total daily dosage of 1.5 ml for each animal.
Control group animals were treated with sterile water for the same period of time. No indications of a systemic effect of the test were observed during the treatment period. A slight mucous irritation was observed in animals treated with the medical preparation approximately 1 hour after the last application and no reactions were observed 24 hours later, thus proving the good tolerability in the hamster oral cavity mucous membranes.
Example 12
Delayed dermal sensitisation study of a preparation containing xyloglucan and glycerol A Guinea pig model, with the test of Magnusson and Kligman
(J. Invest. Dermatol., 268-276, 1969) was used to induce and elicit delayed dermal sensitisation. To induce sensitisation, a test group of 20 animals and a control group of 10 animals were intradermally injected with an emulsion of Freund's complete adjuvant, (anterior sites), the undiluted test item (middle sites) and the test item at a concentration of 50% in an emulsion of Freund's complete adjuvant (posterior sites). One week later this application was boosted by a topical application of the test item at 100% over the injection sites. Control group animals were treated with sterile water for the same period of time. Two weeks after the second induction stage, all animals were challenged by topical application of both the vehicle.
At the end of the study no response was apparent in any animal of the test or control groups and no reaction to the vehicle alone was observed in any animals.
Example 13 Cell toxicity assay of a solution containing xyloglucan and glycerol
The in vitro cytotoxicity of a solution containing xyloglucan and glycerol has been evaluated on BALB/C3T3 cells and measurement of neutral red uptake for cellular toxicity was performed on cultures of BALB/C3T3 cells treated with different concentrations of the test item and at the end of the treatment, the cultures were examined in order to evaluate changes in the morphology of the cells due to toxicity effects of the test item. Negative and positive control were included in the experiment.
The test item was solubilized in culture medium and concentrations used were 39.1 ; 78.1 ; 156; 313; 625; 1250; 2500 and 5000 micrograms/millilitre. Cytotoxicity was analysed after 24 hours treatment time. No change in the morphology of the cells and no relevant reduction in neutral red uptake was observed after treatment with the test item in any experiments at any concentration tested.

Claims

1. Mucoadhesive formulations suitable for the application to human mucous membranes, comprising combinations of a purified natural polymer having xyloglucan structure in aqueous solution at concentrations between 0.05% and 5% by weight and glycerol at concentrations between 10% and 70% by weight.
2. Mucoadhesive formulations according to claim 1 characterized in that the purified natural polymer having xyloglucan structure has viscosity between 150 mPa-sec and 800 mPa sec at the temperature of 25°C operating with a 200 sec"1 shear rate and a rest time of 15 minutes and an absorbance value at 280 nm lower than 0.5 abs units in a 2% by weight aqueous solution at the temperature of 25°C.
3. Mucoadhesive formulations according to claims 1 and 2 characterized in that the human mucous membranes are the nasal, oropharyngeal and vaginal mucous membranes.
4. Mucoadhesive formulations according to claims 1 to 3 characterized in that they can contain active pharmaceutical ingredients and excipients suitable for pharmaceutical preparations and medical devices.
5. Mucoadhesive formulations according to claim 4 in form of controlled release formulations.
6. Mucoadhesive controlled release formulations according to claim 5 in which the controlled release is provided by adjusting the percentage of glycerol in the xyloglucan solution.
7. Pharmaceutical preparations and medical devices suitable for the treatment of human mucous membranes, comprising active pharmaceutical ingredients and excipients together with 0.05% to 5% by weight of a purified natural polymer having xyloglucan structure and 10% to 70% by weight of glycerol.
8. Pharmaceutical preparations and medical devices according to claim 5 characterized in that the purified natural polymer having xyloglucan structure has viscosity between 150 and 800 mPa-sec at the temperature of 25°C operating with a 200 sec"1 "shear rate" and a rest time of 15 minutes and an absorbance value at 280 nm lower than 0.5 abs in a 2% by weight aqueous solution at the temperature of 25°C.
9. Pharmaceutical preparations and medical devices according to claims 5 and 6 characterized in that the active principles are selected from antibiotics, antimycotics, antiprotozoals, antivirals, antiinflammatories, disinfectants, chemotherapeutics, analgesics, antiseptics, mucolytics, antitussives, decongestants, calcium absorption and regulating agents, hormones and vaccines.
10. Pharmaceutical preparations and medical devices according to claims 5 to 7 characterized in that they are in the form of solutions, gels, ovules, sprays, mouthwashes, creams, ointments, unguents and lavages.
11. Pharmaceutical preparations in the form of an oropharyngeal spray containing a mucoadhesive formulation according to claims 1 and 2 together with acid diclofenac or salts thereof.
12. Pharmaceutical preparations in the form of a vaginal gel containing a mucoadhesive formulation according to claims 1 and 2 together with progesterone.
13. Pharmaceutical preparations in the form of a vaginal lavage containing a mucoadhesive formulation according to claims 1 and 2 together with benzidamine hydrochloride.
14. Pharmaceutical preparations in the form of an oral spray containing a mucoadhesive formulation according to claims 1 and 2 together with benzidamine hydrochloride.
15. Pharmaceutical preparations in the form of a nasal spray containing mucoadhesive formulation according to claims 1 and 2 together with calcitonin.
16. Medical devices in the form of a vaginal ovule having moisturizing activity containing a mucoadhesive formulation according to claims 1 and 2 together with excipients.
17. Medical devices in the form of an oropharyngeal spray having softening activity containing a mucoadhesive formulation according to claims 1 and 2 together with excipients.
18. A purified natural polymer having xyloglucan structure characterized by viscosity values between 150 and 800 mPa-sec at the temperature of 25°C by operating with a 200 sec"1 shear rate and a rest time of 15 minutes and by an absorbance value at 280 nm lower than 0.5 abs in a 2% by weight aqueous solution at the temperature of 25°C.
19. A purified natural polymer having xyloglucan structure according to claim 18 characterized in that it is obtained from tamarind seeds.
20. A process for the purification of a natural polymer having xyloglucan structure, that consists in suspending 0.5% to 5% by weight of an extract of raw xyloglucan in a volume of cold distilled water, pouring the obtained suspension in a four time greater volume of boiling distilled water, keeping under boiling and stirring for 15 to 30 minutes, leaving to stand for a time between 10 and 20 hours, centrifuging at 4000 - 8000 rpm for a time between 15 and 30 minutes, filtering the supernatant through a 6 μm polypropylene filter, further centrifuging the filtrate at 12000 - 18000 rpm for a time between 30 and 60 minutes and sterilizing the filtrate through a 0.22 μm polypropylene filter or in autoclave at 1210C for a time between 20 and 40 minutes.
21. A process according to claim 20 characterized in that the raw xyloglucan extract is an extract of tamarind seeds.
22. A process according to claim 20 characterized in that the raw xyloglucan extract is an extract of Detarium senegalense Gmelin.
23. A process according to claim 20 characterized in that the raw xyloglucan extract is an extract of Afzelia africana.
PCT/EP2006/005240 2005-06-06 2006-06-01 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations WO2006131262A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CN2006800176445A CN101180036B (en) 2005-06-06 2006-06-01 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations
DE602006004451T DE602006004451D1 (en) 2005-06-06 2006-06-01 MUCOADHESIVE XYLOGLUCAN-CONTAINING FORMULATION FOR MEDICAL PRODUCTS AND PHARMACEUTICAL PHARMACEUTICAL FORMS
KR1020077028142A KR101337578B1 (en) 2005-06-06 2006-06-01 Mucoadhesive xyloglucan―containing formulations useful in medical devices and in pharmaceutical formulations
EP06754047A EP1898876B1 (en) 2005-06-06 2006-06-01 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical presentations
BRPI0611400A BRPI0611400B8 (en) 2005-06-06 2006-06-01 Muco-adhesive xyloglycan-containing formulations useful in medical devices and pharmaceutical formulations
MX2007015074A MX2007015074A (en) 2005-06-06 2006-06-01 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations.
PL06754047T PL1898876T3 (en) 2005-06-06 2006-06-01 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical presentations
JP2008514019A JP5118633B2 (en) 2005-06-06 2006-06-01 Mucoadhesive xyloglucan-containing preparations useful in medical devices and pharmaceutical preparations
DK06754047T DK1898876T3 (en) 2005-06-06 2006-06-01 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical forms
CA2604768A CA2604768C (en) 2005-06-06 2006-06-01 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations
US11/921,286 US20090081133A1 (en) 2005-06-06 2006-06-01 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical fromulations
IL186655A IL186655A (en) 2005-06-06 2007-10-15 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations and a process for purification of natural polymer having xyloglucan structure
NO20076083A NO338991B1 (en) 2005-06-06 2007-11-26 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations
US13/277,130 US20120088726A1 (en) 2005-06-06 2011-10-19 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical fromulations
US13/747,889 US20130183325A1 (en) 2005-06-06 2013-01-23 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITBO2005A000388 2005-06-06
IT000388A ITBO20050388A1 (en) 2005-06-06 2005-06-06 USEFUL FORMULATION OF MUCOADESIVES IN MEDICAL DEVICES IN PHARMACEUTICAL PREPARATIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/277,130 Division US20120088726A1 (en) 2005-06-06 2011-10-19 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical fromulations

Publications (1)

Publication Number Publication Date
WO2006131262A1 true WO2006131262A1 (en) 2006-12-14

Family

ID=36954507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/005240 WO2006131262A1 (en) 2005-06-06 2006-06-01 Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations

Country Status (22)

Country Link
US (3) US20090081133A1 (en)
EP (1) EP1898876B1 (en)
JP (1) JP5118633B2 (en)
KR (1) KR101337578B1 (en)
CN (2) CN102079794B (en)
AT (1) ATE418324T1 (en)
BR (1) BRPI0611400B8 (en)
CA (1) CA2604768C (en)
CY (1) CY1108875T1 (en)
DE (1) DE602006004451D1 (en)
DK (1) DK1898876T3 (en)
ES (1) ES2318756T3 (en)
IL (1) IL186655A (en)
IT (1) ITBO20050388A1 (en)
MX (1) MX2007015074A (en)
NO (1) NO338991B1 (en)
PL (1) PL1898876T3 (en)
PT (1) PT1898876E (en)
RU (1) RU2403012C2 (en)
SI (1) SI1898876T1 (en)
UA (1) UA90507C2 (en)
WO (1) WO2006131262A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011516548A (en) * 2008-04-11 2011-05-26 セムバイオシス ジェネティクス インコーポレイテッド Controlled release of active agents from oleosomes
ITBO20090775A1 (en) * 2009-12-01 2011-06-02 Alfa Wassermann Spa COMPOSITIONS INCLUDING NON-STEROID ANTI-INFLAMMATORS
WO2011147768A1 (en) 2010-05-24 2011-12-01 Indena S.P.A. Tamarind seed polysaccharide for use in the treatment of inflammatory diseases
WO2011147767A1 (en) 2010-05-24 2011-12-01 Indena S.P.A. Tamarind seed polysaccharide for use in the treatment of microbial infections
RU2452465C2 (en) * 2007-09-06 2012-06-10 Колгейт-Палмолив Компани Dental compositions for xerostomia
US20140364390A1 (en) * 2013-06-11 2014-12-11 Novintethical Pharma, Sagl Xyloglucan-based compositions for the treatment of gastrointestinal disorders
US20150094266A1 (en) * 2013-06-11 2015-04-02 Novintethical Pharma, SA Xyloglucan and protein compositions for the treatment of intestinal disorders
ITMI20132103A1 (en) * 2013-12-16 2015-06-17 Novintethical Pharma Sagl NASAL TOPIC COMPOSITIONS CONTAINING XILOGLUCANS FOR USE AS DECONGESTANTS
WO2015158771A1 (en) 2014-04-15 2015-10-22 Novintethical Pharma Sa Compositions based on xyloglucan and proteins for the treatment of intestinal disorders
EP3103438A1 (en) 2015-06-11 2016-12-14 Novintethical Pharma SA Topical nasal compositions containing xyloglucans for use as decongestans
WO2017207223A1 (en) 2016-05-31 2017-12-07 Novintethical Pharma Sa Compositions for the treatment of intestinal disorders
WO2018007288A1 (en) * 2016-07-08 2018-01-11 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Pharmaceutical composition comprising benzydamine

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1698630T1 (en) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
WO2010088191A1 (en) * 2009-01-27 2010-08-05 Teleflex Medical Incorporated Sputum dissolving suctioning solution for endotracheal and tracheostomy tubes
JP2011001317A (en) * 2009-06-19 2011-01-06 Fumakilla Ltd Cleaning agent for nose
WO2012033634A2 (en) 2010-09-09 2012-03-15 Mary Kay Inc. Topical skin care formulations comprising plant extracts
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (en) 2011-11-23 2021-12-14 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
US9091622B2 (en) 2011-12-20 2015-07-28 Exxonmobil Upstream Research Company Capillary-based calibration standards for measurement of permeability
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
ES2654189T3 (en) 2012-09-12 2018-02-12 Boston Scientific Scimed, Inc. Anti-migration stent adhesive coating
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (en) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. NATURAL COMBINED HORMONE SUBSTITUTION COMPOSITIONS AND THERAPIES
JP2017523138A (en) 2014-07-29 2017-08-17 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． Transdermal cream
US11623008B2 (en) * 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
IT201700108526A1 (en) 2017-09-28 2019-03-28 Alfasigma Spa ORAL COMPOSITIONS FOR THE TREATMENT OF GASTROESOPHAGEAL REFLECTION.
US20220241193A1 (en) * 2019-06-21 2022-08-04 Alfasigma S.P.A. Pharmaceutical compositions in the form of gel containing xyloglucan and alcohols for the controlled release of active ingredients
IT202100010802A1 (en) 2021-05-03 2022-11-03 Alfasigma Spa SOLID MUCOADHESIVE FORMULATION INCLUDING PROBIOTICS FOR USE IN THE PREVENTION AND TREATMENT OF ORAL DYSBIOSIS.
CN114306237A (en) * 2022-01-06 2022-04-12 江苏爱朋医疗科技股份有限公司 Nasal cavity nursing spray and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192640A1 (en) * 2001-05-03 2004-09-30 Gianfranco Gori Use of sucralfate for the treatment of cervical erosion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0429156T3 (en) * 1989-10-31 1995-01-16 Columbia Lab Inc Method of Moisturizing Tissues and Preparations
JPH07289179A (en) * 1994-04-28 1995-11-07 Dainippon Pharmaceut Co Ltd Modifier for boiled rice
US6271001B1 (en) * 1995-03-23 2001-08-07 Bio Polymers Pty. Ltd. Cultured plant cell gums for food, pharmaceutical, cosmetic and industrial applications
JP3909095B2 (en) * 1995-04-11 2007-04-25 大日本住友製薬株式会社 Reversible thermal gelling agent
IT1283911B1 (en) * 1996-02-05 1998-05-07 Farmigea Spa VISCOSIZED OPHTHALMIC SOLUTIONS WITH TAMARIND GUM POLYSACCHARIDES
WO1997029777A1 (en) * 1996-02-13 1997-08-21 Dainippon Pharmaceutical Co., Ltd. Drug delivery system using galactoxyloglucan
JPH11152207A (en) * 1997-11-20 1999-06-08 Shiseido Co Ltd Cosmetic
JPH10259142A (en) * 1997-03-14 1998-09-29 Shiseido Co Ltd Cosmetic
US20050214230A1 (en) * 2004-03-23 2005-09-29 J. B. Chemicals & Pharmaceuticals Ltd. Novel stomatological gel

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192640A1 (en) * 2001-05-03 2004-09-30 Gianfranco Gori Use of sucralfate for the treatment of cervical erosion

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HATEFI A ET AL: "Biodegradable injectable in situ forming drug delivery systems", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 80, no. 1-3, 23 April 2002 (2002-04-23), pages 9 - 28, XP004348621, ISSN: 0168-3659 *
MIYAZAKI S ET AL: "Thermally reversible xyloglucan gels as vehicles for rectal drug delivery", JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 56, no. 1-3, 4 December 1998 (1998-12-04), pages 75 - 83, XP004153921, ISSN: 0168-3659 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2452465C2 (en) * 2007-09-06 2012-06-10 Колгейт-Палмолив Компани Dental compositions for xerostomia
JP2011516548A (en) * 2008-04-11 2011-05-26 セムバイオシス ジェネティクス インコーポレイテッド Controlled release of active agents from oleosomes
ITBO20090775A1 (en) * 2009-12-01 2011-06-02 Alfa Wassermann Spa COMPOSITIONS INCLUDING NON-STEROID ANTI-INFLAMMATORS
WO2011067693A1 (en) * 2009-12-01 2011-06-09 Alfa Wassermann S.P.A. Compositions comprising nonsteroidal anti - inflammatory drugs
WO2011147768A1 (en) 2010-05-24 2011-12-01 Indena S.P.A. Tamarind seed polysaccharide for use in the treatment of inflammatory diseases
WO2011147767A1 (en) 2010-05-24 2011-12-01 Indena S.P.A. Tamarind seed polysaccharide for use in the treatment of microbial infections
US20140364390A1 (en) * 2013-06-11 2014-12-11 Novintethical Pharma, Sagl Xyloglucan-based compositions for the treatment of gastrointestinal disorders
US20150094266A1 (en) * 2013-06-11 2015-04-02 Novintethical Pharma, SA Xyloglucan and protein compositions for the treatment of intestinal disorders
ITMI20132103A1 (en) * 2013-12-16 2015-06-17 Novintethical Pharma Sagl NASAL TOPIC COMPOSITIONS CONTAINING XILOGLUCANS FOR USE AS DECONGESTANTS
US10064886B2 (en) 2014-04-15 2018-09-04 Novintethical Pharma Sa Composition based on xyloglucan and proteins for the treatment of intestinal disorders
US20170027980A1 (en) * 2014-04-15 2017-02-02 Novintethical Pharma Sa Composition based on xyloglucan and proteins for the treatment of intestinal disorders
EP3348273A1 (en) 2014-04-15 2018-07-18 Novintethical Pharma SA Compositions based on xyloglucan and proteins for the treatment of intestinal disorders
WO2015158771A1 (en) 2014-04-15 2015-10-22 Novintethical Pharma Sa Compositions based on xyloglucan and proteins for the treatment of intestinal disorders
US20180318333A1 (en) * 2014-04-15 2018-11-08 Novintethical Pharma Sa Composition based on xyloglucan and proteins for the treatment of intestinal disorders
US10758561B2 (en) 2014-04-15 2020-09-01 Novintethical Pharma Sa Composition based on xyloglucan and proteins for the treatment of intestinal disorders
EP3103438A1 (en) 2015-06-11 2016-12-14 Novintethical Pharma SA Topical nasal compositions containing xyloglucans for use as decongestans
WO2017207223A1 (en) 2016-05-31 2017-12-07 Novintethical Pharma Sa Compositions for the treatment of intestinal disorders
US10780146B2 (en) 2016-05-31 2020-09-22 Devintec Sagl Compositions for the treatment of intestinal disorders
WO2018007288A1 (en) * 2016-07-08 2018-01-11 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Pharmaceutical composition comprising benzydamine
EA037435B1 (en) * 2016-07-08 2021-03-26 Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. Pharmaceutical composition comprising benzydamine

Also Published As

Publication number Publication date
IL186655A (en) 2010-12-30
JP5118633B2 (en) 2013-01-16
JP2008542324A (en) 2008-11-27
CN102079794B (en) 2012-03-28
BRPI0611400A2 (en) 2010-09-08
US20130183325A1 (en) 2013-07-18
DE602006004451D1 (en) 2009-02-05
KR20080016596A (en) 2008-02-21
RU2403012C2 (en) 2010-11-10
IL186655A0 (en) 2008-01-20
NO338991B1 (en) 2016-11-07
CY1108875T1 (en) 2014-07-02
ITBO20050388A1 (en) 2006-12-07
EP1898876B1 (en) 2008-12-24
BRPI0611400A8 (en) 2017-12-26
CA2604768A1 (en) 2006-12-14
NO20076083L (en) 2007-11-26
KR101337578B1 (en) 2013-12-09
ATE418324T1 (en) 2009-01-15
CN102079794A (en) 2011-06-01
MX2007015074A (en) 2008-01-24
UA90507C2 (en) 2010-05-11
BRPI0611400B8 (en) 2021-05-25
PT1898876E (en) 2009-03-05
CA2604768C (en) 2013-07-30
PL1898876T3 (en) 2009-06-30
CN101180036B (en) 2011-07-27
BRPI0611400B1 (en) 2020-04-28
CN101180036A (en) 2008-05-14
DK1898876T3 (en) 2009-03-02
ES2318756T3 (en) 2009-05-01
EP1898876A1 (en) 2008-03-19
US20120088726A1 (en) 2012-04-12
US20090081133A1 (en) 2009-03-26
SI1898876T1 (en) 2009-04-30
RU2007143998A (en) 2009-07-20

Similar Documents

Publication Publication Date Title
CA2604768C (en) Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations
US20150190425A1 (en) Mineral salt-sulfonic acid compositions and methods of use
JP2004535361A (en) Bioadhesive sustained release closed cell foam film
JP2002520281A (en) Vitamin E and its esters for use in the topical treatment of mucosal diseases
JP2001501917A (en) Pharmaceutical composition
US20090035401A1 (en) Composition And Method For Inhibiting Herpesviridae Infections
CN112770765B (en) Composition for preventing and/or treating urogenital mucosa
KR101433396B1 (en) Linseed extract medicament for application to the eye
WO2017098396A1 (en) Synergistic combination of pyrrolidone carboxylic acid and/or salts thereof and hyaluronic acid and/or salts thereof, for use in the treatment and/or prevention of dryness and irritation of the mucosae, and related pharmaceutical formulations
JP5098156B2 (en) Water secretion promoter
ES2628709T3 (en) Composition to control and improve female and male gametogenesis.
AU2014330225A1 (en) A use of the mixture of a salt and sugar in the manufacture of a medicament employed for treating lax vagina syndrome or colpoxerosis disease in a mammal
US9919015B2 (en) Composition and method for inhibiting herpesviridae infections
CN118019528A (en) Compositions and methods for preventing and/or treating diseases associated with IL-23 expression
AU2006294415B2 (en) Composition and method for inhibiting herpesviridae infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 186655

Country of ref document: IL

Ref document number: 2604768

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200680017644.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 9095/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008514019

Country of ref document: JP

Ref document number: 11921286

Country of ref document: US

Ref document number: MX/a/2007/015074

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020077028142

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006754047

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: A20071481

Country of ref document: BY

WWE Wipo information: entry into national phase

Ref document number: 2007143998

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006754047

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0611400

Country of ref document: BR

Kind code of ref document: A2